CONTEXT: Primary aldosteronism is a heterogeneous group of disorders comprising both sporadic and familial forms. Mutations in the KCNJ5 gene, which encodes the inward rectifier K(+) channel 4 (G protein-activated inward rectifier K(+) channel 4, Kir3.4), cause familial hyperaldosteronism type III (FH-III) and are involved in the pathogenesis of sporadic aldosterone-producing adenomas. OBJECTIVE: The objective of the study was to characterize the effects of a newly described KCNJ5 mutation in vitro. PATIENTS AND METHODS: The index case is a 62-year-old woman affected by primary aldosteronism, who underwent left adrenalectomy after workup for adrenal adenoma. Exon 1 of KCNJ5 was PCR amplified from adrenal tissue and peripheral blood and sequenced. Electrophysiological and gene expression studies were performed to establish the functional effects of the new mutation on the membrane potential and adrenal cell CYP11B2 expression. RESULTS: KCNJ5 sequencing in the index case revealed a new p.Y152C germline mutation; interestingly, the phenotype of the patient was milder than most of the previously described FH-III families. The tyrosine-to-cysteine substitution resulted in pathological Na(+) permeability, cell membrane depolarization, and disturbed intracellular Ca(2+) homeostasis, effects similar, albeit smaller, to the ones demonstrated for other KCNJ5 mutations. Gene expression studies revealed an increased expression of CYP11B2 and its transcriptional regulator NR4A2 in HAC15 adrenal cells overexpressing KCNJ5(Y152C) compared to the wild-type channel. The effect was clearly Ca(2+)-dependent, because it was abolished by the calcium channel blocker nifedipine. CONCLUSIONS: Herein we describe a new germline mutation in KCNJ5 responsible for FH-III.
CONTEXT: Primary aldosteronism is a heterogeneous group of disorders comprising both sporadic and familial forms. Mutations in the KCNJ5 gene, which encodes the inward rectifier K(+) channel 4 (G protein-activated inward rectifier K(+) channel 4, Kir3.4), cause familial hyperaldosteronism type III (FH-III) and are involved in the pathogenesis of sporadic aldosterone-producing adenomas. OBJECTIVE: The objective of the study was to characterize the effects of a newly described KCNJ5 mutation in vitro. PATIENTS AND METHODS: The index case is a 62-year-old woman affected by primary aldosteronism, who underwent left adrenalectomy after workup for adrenal adenoma. Exon 1 of KCNJ5 was PCR amplified from adrenal tissue and peripheral blood and sequenced. Electrophysiological and gene expression studies were performed to establish the functional effects of the new mutation on the membrane potential and adrenal cell CYP11B2 expression. RESULTS:KCNJ5 sequencing in the index case revealed a new p.Y152C germline mutation; interestingly, the phenotype of the patient was milder than most of the previously described FH-III families. The tyrosine-to-cysteine substitution resulted in pathological Na(+) permeability, cell membrane depolarization, and disturbed intracellular Ca(2+) homeostasis, effects similar, albeit smaller, to the ones demonstrated for other KCNJ5 mutations. Gene expression studies revealed an increased expression of CYP11B2 and its transcriptional regulator NR4A2 in HAC15 adrenal cells overexpressing KCNJ5(Y152C) compared to the wild-type channel. The effect was clearly Ca(2+)-dependent, because it was abolished by the calcium channel blocker nifedipine. CONCLUSIONS: Herein we describe a new germline mutation in KCNJ5 responsible for FH-III.
Authors: Silvia Monticone; Namita G Hattangady; Koshiro Nishimoto; Franco Mantero; Beatrice Rubin; Maria Verena Cicala; Raffaele Pezzani; Richard J Auchus; Hans K Ghayee; Hirotaka Shibata; Isao Kurihara; Tracy A Williams; Judith G Giri; Roni J Bollag; Michael A Edwards; Carlos M Isales; William E Rainey Journal: J Clin Endocrinol Metab Date: 2012-05-24 Impact factor: 5.958
Authors: Ute I Scholl; Carol Nelson-Williams; Peng Yue; Roger Grekin; Robert J Wyatt; Michael J Dillon; Robert Couch; Lisa K Hammer; Frances L Harley; Anita Farhi; Wen-Hui Wang; Richard P Lifton Journal: Proc Natl Acad Sci U S A Date: 2012-01-30 Impact factor: 11.205
Authors: Kenji Oki; Maria W Plonczynski; Milay Luis Lam; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez Journal: Endocrinology Date: 2012-02-07 Impact factor: 4.736
Authors: Evangelia Charmandari; Amalia Sertedaki; Tomoshige Kino; Christina Merakou; Dax A Hoffman; Michael M Hatch; Darrell E Hurt; Lin Lin; Paraskevi Xekouki; Constantine A Stratakis; George P Chrousos Journal: J Clin Endocrinol Metab Date: 2012-05-24 Impact factor: 5.958
Authors: Paolo Mulatero; Philipp Tauber; Maria-Christina Zennaro; Silvia Monticone; Katharina Lang; Felix Beuschlein; Evelyn Fischer; Davide Tizzani; Anna Pallauf; Andrea Viola; Laurence Amar; Tracy Ann Williams; Tim M Strom; Elisabeth Graf; Sascha Bandulik; David Penton; Pierre-François Plouin; Richard Warth; Bruno Allolio; Xavier Jeunemaitre; Franco Veglio; Martin Reincke Journal: Hypertension Date: 2011-12-27 Impact factor: 10.190
Authors: Murim Choi; Ute I Scholl; Peng Yue; Peyman Björklund; Bixiao Zhao; Carol Nelson-Williams; Weizhen Ji; Yoonsang Cho; Aniruddh Patel; Clara J Men; Elias Lolis; Max V Wisgerhof; David S Geller; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Wenhui Wang; Tobias Carling; Richard P Lifton Journal: Science Date: 2011-02-11 Impact factor: 47.728
Authors: Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams Journal: Nat Rev Endocrinol Date: 2012-12-11 Impact factor: 43.330
Authors: David S Geller; Junhui Zhang; Max V Wisgerhof; Cedric Shackleton; Michael Kashgarian; Richard P Lifton Journal: J Clin Endocrinol Metab Date: 2008-05-27 Impact factor: 5.958
Authors: Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo Journal: Rev Endocr Metab Disord Date: 2019-03 Impact factor: 6.514
Authors: S Monticone; M Tetti; J Burrello; F Buffolo; R De Giovanni; F Veglio; T A Williams; P Mulatero Journal: J Hum Hypertens Date: 2017-04-27 Impact factor: 3.012
Authors: Celso E Gomez-Sanchez; Xin Qi; Elise P Gomez-Sanchez; Hironobu Sasano; Martin O Bohlen; Max Wisgerhof Journal: Mol Cell Endocrinol Date: 2016-10-25 Impact factor: 4.102